Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis

• Main Authors: Jeayeon Park (Author), Yun Bin Lee (Author), Yunmi Ko (Author), Youngsu Park (Author), Hyunjae Shin (Author), Moon Haeng Hur (Author), Min Kyung Park (Author), Dae-Won Lee (Author), Eun Ju Cho (Author), Kyung-Hun Lee (Author), Jeong-Hoon Lee (Author), Su Jong Yu (Author), Tae-Yong Kim (Author), Yoon Jun Kim (Author), Tae-You Kim (Author), Jung-Hwan Yoon (Author)
• Format: Book
• Published: Korean Liver Cancer Association, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background/Aim Atezolizumab plus bevacizumab and lenvatinib are currently available as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC). However, comparative efficacy studies are still limited. This study aimed to investigate the effectiveness of these treatments i...